Cardinal Capital Management Inc. Has $31.05 Million Holdings in Becton, Dickinson and Company (NYSE:BDX)

Cardinal Capital Management Inc. raised its position in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 135,563 shares of the medical instruments supplier's stock after purchasing an additional 7,130 shares during the quarter. Cardinal Capital Management Inc.'s holdings in Becton, Dickinson and Company were worth $31,052,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Bank of Jackson Hole Trust bought a new stake in shares of Becton, Dickinson and Company during the 4th quarter valued at $25,000. Sierra Ocean LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $29,000. REAP Financial Group LLC lifted its position in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 55 shares in the last quarter. Picton Mahoney Asset Management lifted its position in shares of Becton, Dickinson and Company by 61.4% in the fourth quarter. Picton Mahoney Asset Management now owns 142 shares of the medical instruments supplier's stock worth $32,000 after buying an additional 54 shares in the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company during the first quarter worth approximately $34,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Becton, Dickinson and Company stock traded down $2.40 during mid-day trading on Friday, reaching $172.06. The company had a trading volume of 2,276,369 shares, compared to its average volume of 1,971,981. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $163.33 and a 52 week high of $251.99. The company has a 50 day moving average of $183.60 and a 200-day moving average of $213.43. The firm has a market cap of $49.31 billion, a price-to-earnings ratio of 28.58, a PEG ratio of 1.63 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts' consensus estimates of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. The firm had revenue of $5.27 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the prior year, the firm earned $3.17 EPS. The business's revenue was up 4.5% on a year-over-year basis. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be issued a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.42%. The ex-dividend date is Monday, June 9th. Becton, Dickinson and Company's payout ratio is 79.39%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Bank of America lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a report on Thursday, May 1st. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research report on Thursday, May 1st. Piper Sandler downgraded shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their target price for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Barclays lowered their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Finally, Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and lowered their price target for the company from $217.00 to $185.00 in a research report on Thursday, May 22nd. Eight investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $219.22.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the sale, the executive vice president now owns 4,887 shares in the company, valued at $964,107.36. This trade represents a 8.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the sale, the executive vice president now owns 4,575 shares of the company's stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 2,104 shares of company stock valued at $399,675. Company insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.